Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy
· Delayed Price · Currency is EUR 51.20
+0.40 (0.79%)
Aug 14, 2025, 5:35 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Specialty & Primary Care | 1.51B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty & Primary Care Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases | 833.86M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Chemicals | 58.47M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Chemicals Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 2.28B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Uro-Oncology | 399.94M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Uro-Oncology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular | 385.21M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal | 217.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cough and Cold | 137.28M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cough and Cold Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Treatment Areas | 309.31M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Treatment Areas Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endocrinology | 321.69M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endocrinology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Metabolic and Other Areas | 258.94M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Metabolic and Other Areas Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology | 253.23M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zanidip | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zanidip Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zanipress | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zanipress Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urorec | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urorec Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Livazo | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Livazo Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drugs for Rare Diseases | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drugs for Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Seloken/Logimax | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Seloken/Logimax Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Corporate Products | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Corporate Products Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| OTC | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| OTC Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Local Product Portfolios | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Local Product Portfolios Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eligard | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eligard Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 2.28B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Other | 59.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty & Primary Care Operating Income | 426.73M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty & Primary Care Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Operating Income | 212.13M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Operating Income Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | 59.50M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Specialty & Primary Care EBITDA | 524.44M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty & Primary Care EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases EBITDA | 341.33M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases EBITDA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Italy | 336.26M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Italy Growth | 1.11% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International | 2.01B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Growth | 13.36% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe | 1.65B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania | 156.01M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| America | 477.46M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| America Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Africa | 58.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Africa Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Specialty & Primary Care Like-For-Like Growth | 5.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Like-For-Like Growth | 15.70% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Like-For-Like Growth | 9.20% |
Log In |
Log In |
Log In |
Log In | Upgrade
|